- 4.4Impact Factor
- 8.8CiteScore
- 21 daysTime to First Decision
Special Issues
Cancers publishes Special Issues to create collections of papers on specific topics, with the aim of building a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors, who are experts on the topic and all Special Issue submissions follow MDPI's standard editorial process.
The journal’s Editor-in-Chief and/or designated Editorial Board Member will oversee Guest Editor appointments and Special Issue proposals, checking their content for relevance and ensuring the suitability of the material for the journal. The papers published in a Special Issue will be collected and displayed on a dedicated page of the journal’s website. Further information on MDPI's Special Issue polices and Guest Editor responsibilities can be found here. For any inquiries related to a Special Issue, please contact the Editorial Office.
Multiple Myeloma and Immunology: From Pathophysiology to Therapy
Deadline: 31 July 2026
Multi-Omics Approaches to Tumor Antigen Discovery and Immunotherapy Target Identification
Deadline: 31 July 2026
The Role of Peptidases in Cancer
Deadline: 31 July 2026
Contemporary Practices in Immunotherapy-Guided Management of Lung Cancer
Deadline: 31 July 2026
Digital Health and Patient-Reported Outcomes in Cancer Care
Deadline: 31 July 2026
Combination Therapies in Breast Cancer Chemotherapy: Chemoradiation, Targeted Agents, and Immunotherapy
Deadline: 31 July 2026
Radiation Exposure and Cancer
Deadline: 31 July 2026
Recent Advances and Emerging Directions in Lung Cancer Radiotherapy
Deadline: 31 July 2026
From Samples to Solutions: Transforming Cancer Research and Treatment Through Biobanks
Deadline: 31 July 2026
Advances in Lung Ultrasound in Cancer Patients
Deadline: 30 July 2026
Cutting-Edge Nanomedicine Advancements in Cancer Disease
Deadline: 30 July 2026
Ovarian Cancer: Pathogenesis, Molecular Mechanism and Opportunities for Interventions
Deadline: 30 July 2026
of 261

